The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Ovarian serous borderline tumors: A critical review of the literature with emphasis on prognostic indicators
Open accessAbstract
BACKGROUND: The behavior of ovarian serous borderline tumors (SBTs) and significance of various prognostic factors are unclear and difficult to evaluate because of inconsistencies and confusion in the literature. Recent studies have suggested that the morphological features of the primary tumor (presence or absence of micropapillary features) and the peritoneal "implants" (presence or absence of invasive features) can reliably subclassify SBTs into benign and malignant types. The aim of the current review was to test two hypotheses. First, that the alleged malignant behavior of SBTs is poorly documented, and second, that the morphological features of the primary ovarian tumors and the associated peritoneal implants are sufficient to separate SBTs into benign and malignant types, thereby obviating the need for the category. METHODS: 245 studies reporting approximately 18,000 patients with borderline ovarian tumors were reviewed. After excluding series that lacked clinical follow-up or were not analyzable for other reasons, there remained 97 reports that included 4,129 patients. In addition to recurrences and survival, we evaluated the type of peritoneal implants, microinvasion, lymph node involvement, late recurrences, and progression to carcinoma, as these features have served as the underpinning of the concept of "borderline malignancy" or "low malignant potential." RESULTS: Among 4,129 patients with SBTs reviewed, the recurrence rate after a mean follow-up of 6.7 years was 0.27% per year for stage I tumors, the disease-free survival was 98.2%, and the overall disease-specific survival rate was 99.5%. For patients with advanced-stage tumors, the recurrence rate was 2.4% per year. However, the majority (69%) of reported recurrences were not pathologically documented, and only 26 cases (8.4% of all recurrences) were documented to have recurred from an adequately sampled ovarian tumor. The most reliable prognostic indicator for advanced stage tumors was the type of peritoneal implant. After 7.4 years of follow-up, the survival of patients with noninvasive peritoneal inplants was 95.3%, as compared with 66% for invasive implants (P < .0001). Microinvasion in the primary ovarian tumor was associated with a 100% survival rate at 6.7 years, and lymph node involvement was associated with a 98% survival rate at 6.5 years. The few reported cases of stage IV disease, progression to invasive carcinoma, and very late (>20 years) recurrences were poorly documented. The survival for all stages among approximately 373 patients in 6 prospective randomized trials followed for a mean of 6.7 years was 100%. CONCLUSION: Surgical pathological stage and subclassification of extraovarian disease into invasive and noninvasive implants are the most important prognostic indicators for SBTs. Survival for stage I tumors is virtually 100%. Survival for advanced stage tumors with noninvasive implants is 95.3%, whereas survival for tumors with invasive implants is 66%. Invasive implants behave as carcinomas and are most likely metastatic. The precise nature of so-called noninvasive implants is not clear, but they behave in a benign fashion. The presence of a micropapillary architecture in the primary ovarian tumor is a strong predictor of invasive implants. These data support the recommendation that ovarian tumors with a micropapillary architecture be designated "micropapillary serous carcinomas," and those lacking these features, "atypical proliferative serous tumors."
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
Firminger, H. I. (1968) · Armed Forces Institute of Pathology eBooks · Cited by 3,044
Meta-Analysis in Clinical Research
L'ABBÉ, K. A., DETSKY, A. S., & O'ROURKE, K. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-224 · Cited by 1,267
The Medical Review Article: State of the Science
MULROW, C. D. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-3-485 · Cited by 856
(2012) · Elsevier eBooks · doi:10.1016/c2009-0-43803-0 · Cited by 757
Histological Typing of Ovarian Tumours
Scully, R. E. (1999) · Springer eBooks · doi:10.1007/978-3-642-58564-7 · Cited by 654
Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament
Scully, R. E., Young, R. H., & Clement, P. B. (1999) · International Journal of Gynecological Pathology · doi:10.1097/00004347-199907000-00019 · Cited by 617
Young, R. C., Walton, L. A., Ellenberg, S. S., Homesley, H. D., Wilbanks, G. D., Decker, D. G., Miller, A., Park, R., & Major, F. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004123221501 · Cited by 583
Whittemore, A. S., Harris, R., Itnyre, J., Halpern, J., & the Collaborative Ovarian Cancer Group (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116426 · Cited by 525
Guidelines for reading literature reviews.
Oxman, A. D., & Guyatt, G. H. (1988) · Europe PMC (PubMed Central) · Cited by 489
Cited by
Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma
Singer, G., Oldt, R., Cohen, Y., Wang, B. G., Sidransky, D., Kurman, R. J., & Shih, I.-M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.484 · Cited by 854
Self-citationKurman, R. J., & Shih, I.-M. (2008) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e318161e4f5 · Cited by 460
Self-citationSinger, G., Stöhr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D.-F., Wang, T.-L., Kurman, R. J., & Shih, I.-M. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000146025.91953.8d · Cited by 408
Self-citationLevine, D., Brown, D. L., Andreotti, R. F., Benacerraf, B., Benson, C. B., Brewster, W. R., Coleman, B., DePriest, P., Doubilet, P. M., Goldstein, S. R., et al. (2010) · Radiology · doi:10.1148/radiol.10100213 · Cited by 360
Longacre, T. A., McKenney, J. K., Tazelaar, H. D., Kempson, R. L., & Hendrickson, M. R. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000164030.82810.db · Cited by 323
Ovarian Cancer Spheroids Use Myosin-Generated Force to Clear the Mesothelium
Iwanicki, M. P., Davidowitz, R. A., Ng, M. R., Besser, A., Muranen, T., Merritt, M., Danuser, G., Ince, T., & Brugge, J. S. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-11-0010 · Cited by 303
Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary
Gershenson, D. M., Sun, C. C., Lu, K. H., Coleman, R. L., Sood, A. K., Malpica, A., Deavers, M. T., Silva, E. G., & Bodurka, D. C. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000227787.24587.d1 · Cited by 290
Diagnosis, Treatment, and Follow-Up of Borderline Ovarian Tumors
Fischerova, D., Zikan, M., Dundr, P., & Cibula, D. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0139 · Cited by 279
Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria
Hauptmann, S., Friedrich, K., Redline, R., & Avril, S. (2017) · Virchows Archiv · doi:10.1007/s00428-016-2040-8 · Cited by 270
du Bois, A., Ewald-Riegler, N., de Gregorio, N., Reuss, A., Mahner, S., Fotopoulou, C., Kommoss, F., Schmalfeldt, B., Hilpert, F., Fehm, T., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.01.035 · Cited by 252
Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges
Shih, I.-M., & Kurman, R. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0755 · Cited by 142
Self-citation
Metadata
- Authors
- Seidman, J. D., & Kurman, R. J.
- Venue
- Human Pathology
- Publisher
- Elsevier BV
- Published
- 2000-05
- Volume
- 31
- Issue
- 5
- Pages
- 539-557
- ISSN
- 0046-8177 (ISSN-L)
- OpenAlex
- W2149122549
- Cited by
- 410
- References
- 108
- FWCI
- 11.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.